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Recombinant tissue-type plasminogen activator (rt-Pa]
and single chain urokinase-type plasminogen activator
(scu-Pa ) are thrombolytic agents, characterized by a
high but not absolute degree of fibrin specificity that is
mediated through different molecular mechanisms. Both
activators are still under clinical investigation but it has
become apparent tbat their therapeutic dose in humans
is high and associated witb a variable degree of systemic
activation of the fibrinolytic system and fibrinogen
breakdown. Therefore, the quest for further improve-
ment of agents and therapeutic schemes continues. Re-
search is being pursued in this area along the following
lines: I) tissue-type plasminogen activator (t-PA) and
single chain urokinase-type plasminogen activator in molar
ratios of 4 : I to I :4 do not act synergistically on throm-
bolysis in a plasma environment in vitro. but display
significant synergism in animal models of thrombosis.
In pilot studies in patients with coronary artery occlu-
sion . rt-PA and scu-Pa are markedly synergistic and
efficient thrombolysis can be obtained with a fivefold
The fibrinolytic system, which is responsible for the removal
of fibrin from the blood vessel s, contains a proenzyme .
pla sminogen. which can be converted to the active enzyme
plasmin by several different types of plasminogen activa-
tors . Inh ibition of the fibrinolytic sys tem can occur at the
level of the plasminogen activ ators or at the level of plasmin .
Plasminogen Activators
Plasm inogen act ivators arc serine proteases with a high
spec ificity for their natural substrate plasminogen . They
convert plasminogen to plasmin by hydrol ysis of the argi-
nine 560- valin e 561 peptide bond . Plasmin is respon sible
for the degradation of fibrin . but it has a poor substrate
spec ific ity and may also degrade severa l other plasma pro-
teins including fibrino gen , facto r Y and factor YIlL Exten -
sive activa tion of the fibrinol ytic system, which commonl y
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lower combined dose than that of the separate agents.
The combined dose does not seem to induce systemic
fibrinogen breakdown. 2) Deletion mutants of rt-PA can
be constructed with a significantly prolonged half-life in
vivo, and a better thrombolytic potential after bolus in-
travenous injection. 3) Cleavage site-specific mutants of
scu-PA that abolish the conversion to urokinase may
have a higher fibrin specificity. The mutants constructed
thus far, however, seem to have a lower specific throm-
bolytic activity. 4) Chimeric molecules obtained by fu-
sion of eDNA encoding the NHrterminal region of t-Pa,
responsible for its fibrin affinity and eDNA encoding the
COOH-terminal region of scu-Px , responsible for its
enzymatic properties, combine both mechanisms of fi-
brin specificity, at least to some extent.
It is anticipated that some of these research lines will
yield improved thrombolytic agents or therapeutic reg-
imens.
(J .4m Coli Cardio! /987;1O:/IR-58)
occurs during infusion of the thrombolytic agents strepto-
kinase or urokinase. is. therefore. usually associated with
a "sys temic fibrinolytic state " charact erized by plasmino-
gen activat ion . depletion of alpha--antiplasmin (the circu-
lat ing physiologic inhibitor of plasmin ) and fibrino gen
breakdown. Physiologic fibrinol ysis . however . which is re-
sponsible for the removal of fibrin deposit s from the vasc ular
bed . is highl y librin specific and not associated with sys temic
activatio n of the fibrinolyt ic sys tem. Thi s fibr in spec ificity
of physiologic fibrinolysis results fro m spec ific molecul ar
interactions among the reactant s: plasm inogen act ivator.
plasmin ogen . fibrin and alph a --antipl asmin ( I) .
Classification of plasminogen activators. Two main
classes of plasminogen act ivators have been identified : one
related to the acti vator found in tiss ues (tiss ue-type plas-
minogen activator it-PAil and the other related to the ac-
tivator found in urine (uroki nase-type plasminogen activator
lu-PAIl. Urokinase-type plasm inogen activ ator is normally
obtained as a two chain molecu le. hut a single chain form
(scu-PA) has also been isolated.
Th rombolytic agents are plasm inogen act ivators that con-
vert the inactive proenzyme plasminogen of the blood fi-
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brinolytic system to plasmin. a serine protease that degrades
the fibrin of a blood clot. Thrombolytic agents can be clas-
sified into two main groups: I) the "classic" thrombolytic
agents, streptokinase and urokinase, and 2) the "new gen-
eration" thrombolytic agents, recombinant tissue-type plas-
minogenactivator (rt-PA). single chain urokinase-type plas-
minogen activator (scu-PA) and acylated plasminogen
streptokinase activator complex (APSAC).
Thrombolysis with the classic thrombolytic agents strep-
tokinase and urokinase is generally associated with the gen-
eration of free circulating plasmin. which induces a "sys-
temic fibrinolytic state" and extensive fibrinogen degradation.
The new generation thrombolytic agents are assumed to be
more clot selective as a result of molecular interactions that
render them more effective at the fibrin surface than in the
circulating blood. The mechanism of fibrin selectivity is.
however, different for each activator.
Tissue-type plasminogen activator (t·PA). This pro-
tease is relatively, but not totally. inactive in the absence
of fibrin. and fibrin strikingly enhances the activation rate
of plasminogen by t-PA (2). Fibrin essentially increases the
stability of the Michaelis complex by creating an additional
interaction between t-PA and its substrate. The high affinity
of t-PA for plasminogen in the presence of fibrin thus allows
its preferential activation on the fibrin clot. The clot spec-
ificity of the activation of plasminogen by t-PA in vivo is.
however, only relative and not absolute (3). The throm-
bolytic efficacy and fibrin specificity of natural and recom-
binant t-PA (rt-PA) has been demonstrated in animal models
of pulmonary embolism. venous thrombosis and coronary
artery thrombosis (for references see Ref. 4). In several
multicenter clinical trials in patients with acute myocardial
infarction, intravenous infusion of rt-PA resulted in coro-
nary repcrfusion in approximately 70% of patients, but was
associated with an average decrease of the plasma fibrinogen
level by 30 to 50(le (5-7). At the high infusionratescurrently
used to obtain rapid coronary artery repcrfusion in patients
with acute myocardial infarction (40 to 90 mg over I hour).
the plasma level of rt-PA is raised to approximately 1.000
times the physiologic concentration. Under these conditions
systemic activation of the fibrinolytic system occurs to a
variable degree in vivo OS).
Single chain urokinase plasminogen activator (scu-Pa),
This protease docs not activate plasminogen in plasma be-
cause of competitive inhibition. The fibrin specificityof the
activation of plasminogen by scu-PA is due to reversal by
fibrin of this inhibited state (9). The detailed molecular
interactions responsible for its unique action remain, how-
ever, to be more precisely defined. The fibrin specificity of
thrombolysis with scu-PA is also only relative (10, II). Clot-
specific thrombolysis by natural or recombinant scu-PA has
been demonstrated in animal models of venous thrombosis
and coronary artery thrombosis (for references see Ref. 4).
In patients with acute myocardial infarction, intravenous
infusion of 40 to 70 rng scu-PA over 1 hour resulted in
coronary artery reperfusion in 75% of the patients but a
pronounced decrease of fibrinogen was observed in 25% of
the patients (10, II),
Anisoylated plasminogen SK (APSAC). APSAC is an
inactive derivative of the plasminogen-streptokinase com-
plex, obtained by acylation of the active center of plasmin-
ogen. It does not interact with plasminogen until it is reac-
tivated by spontaneous deacylation. It was hoped that APSAC
would have an affinity for fibrin and a certain fibrin selec-
tivity due 10 reactivation after adsorption to the fibrin sur-
face, but no significant fibrin selectivity of thrombolysis has
been observed in humans 02).
New Developments in Fibrin-Speclfic
Thrombolytic Therapy
With the development of the fibrin-specific thrombolytic
agents rt-PA and scu-PA, many problems relating to the
optimal use of these agents remain unsolved. In addition,
it is becoming apparent that the fibrin specificity of these
agents is not as pronounced in humans as was anticipated
from several animal models, Therefore, the quest for throm-
bolytic agents with better fibrin selectivity continues, We
are at present pursuing four main lines of research to obtain
better agents or regimens for fibrin-specific thrombolytic
therapy.
I. Synergism between t-PA and scu-Pa, Because the
mechanisms that regulate the fibrin specificity of t-PA and
scu-PA arc entirely different, combined infusions of both
agents might act synergistically and be devoid of side effects
on the hemostatic system. The mechanism of the fibrin
specificity of thrombolytic agents is complex because it is
regulated by molecular interactions between several com-
ponents of the fibrinolytic system, such as between plas-
minogen and fibrin. between plasmin and alpha--antiplas-
min, between t-PAand fibrin, between t-PAand plasminogen,
between scu-PA and plasminogen, between scu-PA and a
competitive inhibitor in plasma and between this scu-
PA/inhibitor complex and fibrin. Furthermore, the dem-
onstration of synergism between drugs cannot be based on
a simple comparison of the effects of the agents when used
in combinationand the sum of their effects whenused alone.
Indeed, the correct method for analyzing drug interactions
is more laborious and involved, as demonstrated by Ber-
enbaum (13).
Synergism (~l t-PA and scu-Pn. Synergism is defined as
a greater effect of a combination of agents than is expected
from the effectiveness of its constituents. However, what
is to he expected from a combination or agents is not nec-
essarily the sum of the effects of its constituents when used
separately. This would only apply if the dose-response curves
of the drugs were linear. which is usually not the case with
biologically active agents. Therefore, the effect of a com-
bination of drugs can rarely be expected to be the sum or
the effects of its constituents, and the assumption that it
rxcc V,,1. 10. 1\0. 5
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should may lead to absurd conclusions (13). The proper way
to compare different agents having the same effect and non-
linear dose-effect curves is to titrate them to the same end
point (equi-effective dose). Synergism as pharmacologically
defined will then occur when the same specified effect is
obtained with combination of the two drugs in fractions of
the equi-effective dose that are significantly <:I. Further-
more, synergism of two agents like t-PA and scu-Px will
be therapeutically useful only if it occurs with total amounts
of the drugs, when used in combination, that are signifi-
cantly smaller than the equi-effective dose of the most active
agent when used alone.
In vitro studies. With these concepts in mind. we have
performed a detailed study on the synergism of rt-PA and
scu-PA in vitro using an iodine-125-fibrin-labeled plasma
clot immersed in citrated plasma (14). Selected data that
are most illustrative of the conclusions reached in that study
are summarized in Figure I. The equi-effective doses of
rt-PA and scu-PA that induced 50% clot lysis in 2 hours
were 4.5 ± 2.3 and 23 ± 4 nM (mean ± SD). respectively.
With molar ratios of t-PA to scu-PA of 4: I, 1: I and 1:4.
50% clot lysis in 2 hours was obtained with a total con-
ccntration of 3.8 ± 1.0. 5.5 ± 3.2 and 10 ± 4.6 nM.
respectively. Because none of the combinations were found
to bc significantly more thrombolytic or significantly more
fibrin specific than an equivalent amount of t-PA alone. we
concluded that no (useful) synergism between t-PA and scu-
PA can be demonstrated in vitro. Application of the formula
of Berenbaum (13) to the data of Figure I yields sums of
fractional equi-cffcctive doses (50% clot lysis in 2 hours)
which, for the ratios of t-PA to scu-PA of 4: I. 1: 1 and
1:4, are 0.73 -+ 0.20. 0.70 ± 0.19 and 0.79 ± 0.24
(p> 0.05).
Figure 1. In vitro clot lysis by tissue-type plasminogen activator
(t-PAl. urokinase-type plasminogen activator (seu-PAj and mix-
tures thereof. The data represent percent clot lysis after 2 hours.
(e) t-PA; (.) scu-PA; (.) t-PA/scu-PA, molar ratio 1: 4: (Tj t-
PAlscu-PA. molar ratio l: I: (A) t-PA/scu-PA. molar ratio 4: I.
(Redrawn. with permission. from Collen D ct al. 1141.)
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CONCENTRATION InMI
The conclusions from our in vitro study (14) are in ap-
parent conflict with those of several recent preliminary re-
ports based on nearly identical in vitro findings (15-17). In
those studies, however, the very marked nonlinearity of the
dose-response curve of scu-PA or the lower specific activity
of scu-PA as compared with t-PA, or both, was disregarded.
At present only one of these studies has been published (18)
and it claims that small amounts of t-PA combined with
large amounts of scu-PA (molar ratios of I :6 to I : 12) show
a marked synergistic action. Apart from the fact that syn-
ergism was not evaluated by the equi-effective dose titration
method (13), the best combination required a severalfold
higher total amount of plasminogen activator than the equi-
effective dose of I-PA alone. Consequently, the extrapo-
lation from these in vitro findings that combination therapy
in humans may have important clinical and economic im-
plications appears to be unjustified.
In l'im studies. In vivo, however, in a jugular vein
thrombosis model in the rabbit, significant synergism be-
tween t-PA and scu-PA and between t-PA and urokinase
for thrombolysis was observed (19). When t-PA and scu-
PA were infused in a molar ratio of approximately I: 3, the
specific thrombolytic activity of the mixture was more than
threefold higher than was anticipated on the basis of additive
effects of hath agents. Preliminary results in patients with
acute myocardial infarction (20) suggest that rt-PA and scu-
PA and rt-PA and urokinase act synergistically also in hu-
mans. Indeed, combinations of 10 mg rt-PA and 3 rng scu-
PA produced coronary artery reperfusion in three patients
with acute myocardial infarction and angiographically con-
firmed coronary artery occlusion. Combinations of 10 rng
rt-PA and 300,000 IU urokinase induced reperfusions in
three of four patients. Although these results are clearly of
a preliminary nature and need to be confirmed in larger
numbers of patients, we have more recently demonstrated
that combinations of 10 mg rt-PA and 10 mg recombinant
single chai n urokinase-type plasminogen activator (rscu-PA)
are indeed very effective and in addition produce coronary
thrombolysis in the absence of systemic fibrinogen break-
down (21al-
This demonstration ojmarked in vivo synergism contrasts
with the lack, or the at best marginal extent, of synergism
observed in the in vitro clot lysis systems. Obviously, ad-
ditional factors found only in vivo are involved. This is
supported by the observation that the dose-response curve
of in vivo thrombolysis with scu-PA is linear, whereas a
clear threshold phenomenon of clot lysis in a plasma en-
vironment is observed in vitro (14,19).
In £II/ elji}rt to obtain more information on the mechanism
ofth« in vivo synergism between thrombolytic agents, we
have in the rabbit jugular vein thrombosis model (21) infused
I) rt-PA and scu-PA simultaneously over 4 hours; 2) rt-PA
over I hour, then 15 minutes later scu-PA over 2 hours;
and 3) sCLl-PA over I hour, then 15 minutes later It-PA over
2 hours. Significant synergism on thrombolysis was ob-
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served when rt-PA and seu-PA were infusedsimultaneously
or when rt-PA was followed by seu-PA, but not when
scu-PA was followed by rt-PA. This might suggest that
"predigestion" of the clot by wayof plasminogen activation
with rt-PA or any other plasminogen activators renders it
more sensitive to thrombolysis with scu-PA. However, in-
jection of urokinase followed by scu-PA has no synergistic
effect.
2. Mutants of rt-PA. Mutants of rt-PA, which have a
higher fibrin affinity, a longer in vivo half-life or an im-
proved fibrin specificity, may constitute potentially useful
thrombolytic agents. Larsen et al. (22) recently found that
specifically mutagenized rt-PA molecules can be obtained
with a more than fivefold prolonged half-life in rats. The
thrombolytic and pharmacokinetic properties of one of these
variants were studied (23) in a canine model with copper
coil-induced thrombosis of the left anteriordescending coro-
nary artery. The deletion mutant had a markedly slower
disposition rate from plasma than did intact t-PA, which
rendered it relatively more effective than natural t-PA after
bolus injection.
3. Mutants of seu-PA. This protease differs markedly
from urokinase with respect to fibrin-specific thrombolytic
properties; therefore site-specific mutagenesis of scu-PA
aroundthe cleavage site mightyield a morestable molecule.
We (24) have recently constructed and characterized lysine
158 mutants of scu-PA in which lysine 158 was exchanged
with glycine or with glutamic acid.
The mutant forms of scu-PA, in contrast to the natural
scu-PA, could not be convertedintoan amidolytieallyactive
two chain form (tcu-PA) by plasmin and did not cause lysis
of an iodine-125-fibrin labeled plasma clot immersed in
citratedhuman plasma. However, in a purifiedsystem, both
scu-PA-glycine 158 and scu-PA-glutamic acid 158 activate
plasminogen after Michaelis-Menten kinetics, with a much
loweraffinity (K m = 60 to 80 jJ.,M) but witha highercatalytic
rate constant (k, = 0.0 I s- I) as compared with the wild
type scu-PA (Km = 1.0 f.LM, k2 = 0.002 s - I), indicating
that conversion of scu-PA to tcu-PA is not a prerequisite
for theactivation of plasminogen. However, lysine-IS8 seems
to be important for the stability of the Michaelis complex
between scu-PA and plasminogen. A low molecular weight
form of scu-PA with leucine 144 in the amino terminal
position was found to be functionally indistinguishable from
intact scu-PA (25). Low molecular weight scu-PA may
therefore be preferable to intact scu-PA for the large scale
production of this molecule by recombinant DNA technol-
ogy.
4. Hybrids of t-PA and scu-Pa, On the basis of the
hypothesis that the fibrin selectivityof t-PA and scu-PA are
localized in different structural domains, we recently (26)
produced a hybrid molecule that has both the fibrin affinity
Figure 2. Schematic representation of the
fusion protein consisting of amino acids
I to 263 of tissue-type plasminogen ac-
tivator and amino acids 144 to 411 of
urokinase-type plasminogen activator.
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oft-PA and the enzymatic properties of scu-PA. This hybrid
consists of amino acids serine-l through threonine 2fi3 of
rt-PA fused to amino acids leucine-144 through leucine-411
of scu-PA (Fig. 2). The protein has an approximate M, of
70,000 and, on immunoblotting, reacts with rabbit antisera
developed against human t-PA and human u-PA. The uro-
kinase-like amidolytie activity (S-2444) of the protein is
only 320 IUlmg but increases to 43,000 IU/mg after treat-
ment with plasmin, which results in conversion of the single
chain molecule (t-PA/scu-PA) to a two chain molecule (t-
PA/tcu-PA).
Both proteins activate plasminogen directly with Mi-
chaelis constant (Km ) 1.5 p.,M and catalytic rate constant
(k2) 0.0058 s I for t-PA/scu-PA and with K", - SO p.,M
and k2 = 5.6 s- I for t-PA/tcu-PA, and both bind specifically
to fibrin, although more weakly than t-PA. In an in vitro
systemcomposed of a whole human 12'I-fibrin labeled plasma
clot immersed in human plasma, the t-PA/tCll-PA hybrid
has a higher fibrin selectivity of clot lysis than docs tcu-
PA, but this difference was not evident between t-PA/scu-
PA and scu-PA. It remains to be investigated whether these
t-rA/u-PA hybrid proteins, which combine the fibrinaffinity
of t-PA with the enzymatic properties of u-PA (either
scu-PA or tcu-Pa) , produce improved fibrin-mediated plas-
minogen activation in vivo.
Conclusions. We believe that some of these research
lines will yield "new generation" thrombolytic agents or
therapeutic regimens that are superior to rt-PA or scu-PA,
or both, in terms of specific thrombolytic activity and fibrin
specificity.
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